Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.

The multikinase inhibitor regorafenib (BAY 73-4506) exerts both anti-angiogenic and anti-tumorigenic activity in adult solid malignancies mainly advanced colorectal cancer and gastrointestinal stromal tumors. We intended to explore preclinically the potential of regorafenib against solid pediatric m...

Full description

Bibliographic Details
Main Authors:	Estelle Daudigeos-Dubus, Ludivine Le Dret, Claudia Lanvers-Kaminsky, Olivia Bawa, Paule Opolon, Albane Vievard, Irène Villa, Mélanie Pagès, Jacques Bosq, Gilles Vassal, Dieter Zopf, Birgit Geoerger
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4658168?pdf=render

Similar Items

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
by: Dieter Zopf, et al.
Published: (2016-11-01)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
by: Anne Catherine Harttrampf, et al.
Published: (2021-07-01)

EVALUATION DE L’INHIBITION DE L’ANGIOGENESE DANS LE NEUROBLASTOME ET CARACTERISATION DE MECANISMES DE RESISTANCE
by: Daudigeos -Dubus, Estelle
Published: (2014)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care
by: Zhe Zhou
Published: (2020-01-01)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
by: Qiang Fu, et al.
Published: (2019-07-01)

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models
by: Emily M. Harris, et al.
Published: (2018-07-01)

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
by: Dennis Doleschel, et al.
Published: (2021-09-01)

Triggering of Suicidal Erythrocyte Death by Regorafenib
by: Jens Zierle, et al.
Published: (2016-01-01)

Experience with regorafenib in the treatment of hepatocellular carcinoma
by: Alessandro Granito, et al.
Published: (2021-05-01)

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
by: Ann-Lii Cheng, et al.
Published: (2021-03-01)

Regorafenib: from clinical research to clinical practice
by: M Yu Fedyanin, et al.
Published: (2017-09-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Management of regorafenib-related toxicities: a review
by: Saravanan K. Krishnamoorthy, et al.
Published: (2015-09-01)

Research advances in regorafenib in treatment of hepatocellular carcinoma
by: CHEN Weibo
Published: (2017-12-01)

Targeting gastrointestinal stromal tumors: the role of regorafenib
by: Schroeder B, et al.
Published: (2016-05-01)

Regorafenib suppresses sinusoidal obstruction syndrome in rats
by: Okuno, Masayuki
Published: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
by: Fotios Loupakis, et al.
Published: (2020-10-01)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Barbara Melosky
Published: (2016-01-01)

Regorafenib治疗肝癌的临床研究进展
by: QI Xingshun
Published: (2014-03-01)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
by: Kawakami K, et al.
Published: (2019-10-01)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
by: Yan Y, et al.
Published: (2015-10-01)

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
by: Nicola Personeni, et al.
Published: (2018-06-01)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
by: Festino L, et al.
Published: (2013-04-01)

Preclinical development of CD126 CAR-T cells with broad antitumor activity
by: Ameet K. Mishra, et al.
Published: (2021-01-01)

In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model
by: Libo Zhang, et al.
Published: (2009-05-01)

The antitumor mechanisms of aerobic exercise: A review of recent preclinical studies
by: Ningxin Jia, et al.
Published: (2021-09-01)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
by: Wan Wang, et al.
Published: (2019-10-01)

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
by: Lipika Goyal, et al.
Published: (2020-07-01)

In-Vitro and In-Vivo Establishment and Characterization of Bioluminescent Orthotopic Chemotherapy-Resistant Human Osteosarcoma Models in NSG Mice
by: Maria Eugénia Marques da Costa, et al.
Published: (2019-07-01)

Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
by: Ebrahim Rahmani Moghadam, et al.
Published: (2020-09-01)

Regorafenib Enhances Lethality of Sildenafil and Curcumin in Colorectal Cancer Cells
by: Owusu, Kervin Benjamin
Published: (2019)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
by: Swathi Veeroju, et al.
Published: (2021-02-01)

Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy
by: Danielle Ferraro, et al.
Published: (2014-09-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
by: Anna Strasma, et al.
Published: (2021-03-01)

Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity
by: Durvanei A. Maria, et al.
Published: (2019-01-01)

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)

Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
by: Martin Glas, et al.
Published: (2019-12-01)

Cannot write session to /tmp/vufind_sessions/sess_oj3gf0d4u7mcd1tt5eqrh8okg3